The Source Blog
Recent Action in Pharmaceuticals
Introduced: 2023 Status: In Process
As introduced, prohibits a healthcare prescriber from issuing a prescription for a dual-purpose prescription medication for diabetes to a person in this state if the person does not have a diagnosis of diabetes; defines a …
SB 1314 (see companion bill HB 1419) – Tennessee
Introduced: 2023 Status: In Process
As introduced, prohibits a healthcare prescriber from issuing a prescription for a dual-purpose prescription medication for diabetes to a person in this state if the person does not have a diagnosis of diabetes; defines a …
HB 0282 (see companion bill SB 0869) – Tennessee
Introduced: 2023 Status: In Process
As introduced, authorizes as part of the practice of pharmacy the prescribing of dietary fluoride supplements, certain immunization agents, opioid antagonists, and certain other drugs and products; makes various other changes to pharmacy practice. – …
SB 0869 (see companion bill HB 0282) – Tennessee
Introduced: 2023 Status: In Process
As introduced, authorizes as part of the practice of pharmacy the prescribing of dietary fluoride supplements, certain immunization agents, opioid antagonists, and certain other drugs and products; makes various other changes to pharmacy practice. – …
HB 1754 (see companion bill SB 622) – Texas
Introduced: 2023 Status: Inactive / Dead
Relating to the disclosure of certain prescription drug information by a health benefit plan.
SB 622 (see companion bill HB 1754) – Texas
Introduced: 2023 Status: Enacted
Relating to the disclosure of certain prescription drug information by a health benefit plan.
HB 2021 (see companion bill SB 1137) – Texas
Introduced: 2023 Status: Inactive / Dead
Relating to applicability of certain insurance laws to pharmacy benefit managers.
Next | See all Legislation Records
District Court: District of Columbia Status: Pending
A complaint filed by Merck, a multinational pharmaceutical company, alleges that the drug price negotiation process detailed in the Inflation Reduction Act (IRA) violates the …
FTC v. Amgen Inc. & Horizon Therapeutics Plc. – Federal
District Court: Northern District of Illinois, Eastern Division Status: Pending
The FTC filed a lawsuit requesting a temporary restraining order and preliminary injunction to block Amgen Inc. from acquiring Horizon Therapeutics. Amgen agreed to purchase …
PhRMA v. Stolfi – Oregon
District Court: District Court of Oregon Status: Pending
PhRMA is challenging Oregon’s drug price transparency laws HB 4005, 2018 (Disclosure Law) and HB 2658, 2019 (Advance Notification Law) alleging that the laws are …
Pharmaceutical Care Management Association (PCMA) v. Mulready – Oklahoma
District Court: District Court of Western District of Oklahoma Status: Decided
The 2019 Oklahoma law, Patient’s Right to Pharmacy Choice Act, targets PBM conflict of interest by prohibiting higher reimbursement rates for PBM-owned pharmacies and bans …
State of Ohio v. OptumRx – Ohio
District Court: Ohio Court of Common Pleas (Franklin County) Status: Pending
On March 15, 2019, Ohio’s attorney general Dave Yost sued OptumRx in Ohio state court, claiming that between 2015 and 2018, the PBM failed to pass …
Minnesota v. Sanofi-Aventis U.S. LLC – Minnesota
District Court: District Court of New Jersey Status: Pending
Minnesota’s attorney general filed a suit accusing Sanofi, Eli Lilly, and Novo Nordisk, the three largest manufacturers of insulin, of price gouging. The lawsuit, filed in …
Pharm. Care Mgmt. Ass’n v. Tufte – North Dakota
District Court: District of North Dakota Status: Pending
Trade association representing pharmacy benefit managers (PBMs) brought action against North Dakota state officials in their official capacities, alleging that Employee Retirement Income Security Act …
Next | See all Litigation Records
News & Opinions
Articles & Reports
Business Group on Health August 22, 2023
NEJM July 8, 2023
Health Affairs Forefront July 6, 2023
Trends in Pharmaceuticals
2019 Pharmaceutical Legislation
Click on highlighted states to see all legislative action to regulate pharmaceutical price and competition in the 2019 session.
-
Key:
- Enacted
- Considered
- No Legislative Session
Price Transparency
Click on highlighted states to see all legislative action to regulate pharmaceutical price and competition in the 2018 session.
-
Key:
- Enacted
- Considered
- No Legislative Session
Rate Setting
Click on highlighted states to see all legislative action to regulate pharmaceutical price and competition in the 2018 session.
-
Key:
- Enacted
- Considered
- No Legislative Session
Price Gouging
Click on highlighted states to see all legislative action to regulate pharmaceutical price and competition in the 2018 session.
-
Key:
- Enacted
- Considered
- No Legislative Session
Drug Importation
Click on highlighted states to see all legislative action to regulate pharmaceutical price and competition in the 2018 session.
-
Key:
- Enacted
- Considered
- No Legislative Session
Pharmacy Gag Clause Regulation
Gag clause regulation includes laws that allow pharmacists to disclose costs to insured patients and those that prohibit pharmacists from collecting more in cost-sharing from the insured patient than the cash price. See The Source’s Spotlight on 2018 State Drug Legislation Part 3 and 2018 legislation chart for more information.
-
Key:
- Enacted
- Considered
- No Legislative Session
PBM Regulation
Click on highlighted states to see all legislative action to regulate pharmaceutical price and competition in the 2018 session.
-
Key:
- Enacted
- Considered
- No Legislative Session
Pharma Other
Click on highlighted states to see all legislative action to regulate pharmaceutical price and competition in the 2018 session.
-
Key:
- Enacted
- Considered
- No Legislative Session